SAB Biotherapeutics, Inc. announced that Michael G. King Jr. has been named Chief Financial Officer. Mr. King has extensive experience and prior success as an award-winning biotechnology research analyst and senior advisor with more than 25 years of experience with investors, banking institutions and thought leaders in various pharmaceutical disciplines. Mr. King, who starts his new role on Oct.

30, replaces Russell Beyer, who is expected to step down on Nov. 15 and remain a senior advisor with the company through the end of the year. Mr. Kings record of achievement includes successful engagements with Hambrecht &Quist, Alex Brown &Sons Robertson Stephens, Vector Securities, Bank of America, Rodman &Renshaw, JMP Securities, and HC Wainwright.

Most recently, he was Co-Head of Healthcare Research at EF Hutton Group. Mr. King received his BA in Finance from the Bernard M. Baruch College of the City University of New York. Mike has an outstanding track record of best-in-class relationships in the investment community and is a sought-after advisor for companies seeking strong value creation, said Eddie J. Sullivan, Ph.D., co-founder, President, and Chief Executive Officer of SAB Biotherapeutics.